NovaCal Pharmaceuticals

NovaBay Pharmaceuticals, formerly known as NovaCal Pharmaceuticals, is a biopharmaceutical company that develops and commercializes non-antibiotic anti-infective products. The company's core technology is the Aganocide platform, which creates synthetic versions of antimicrobial molecules produced by the human immune system to combat infections without inducing bacterial resistance. Its lead product, Avenova, was a widely used prescription and over-the-counter treatment for blepharitis and dry eye, though the company divested this asset in early 2025. NovaBay has historically targeted indications in dermatology, ophthalmology, and urology, including impetigo and catheter-associated urinary tract infections. The company is headquartered in Emeryville, California, and is publicly traded on the NYSE American under the symbol NBY.